Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)‘s stock had its “buy” rating reaffirmed by investment analysts at Oppenheimer Holdings, Inc. in a report issued on Thursday. They presently have a $21.00 target price on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price target indicates a potential upside of 23.17% from the company’s previous close.

Several other research analysts also recently weighed in on the stock. Piper Jaffray Companies upped their price objective on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday. Jefferies Group LLC restated a “buy” rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 price objective on the stock in a report on Tuesday, August 8th. Finally, HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.63.

Vanda Pharmaceuticals (NASDAQ VNDA) traded up 2.794% during mid-day trading on Thursday, hitting $17.475. 2,387,652 shares of the stock traded hands. The company has a 50 day moving average price of $16.27 and a 200-day moving average price of $15.12. The stock’s market capitalization is $783.89 million. Vanda Pharmaceuticals has a one year low of $12.70 and a one year high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm had revenue of $42.06 million for the quarter, compared to the consensus estimate of $40.31 million. During the same quarter in the prior year, the company posted $0.01 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. Equities analysts anticipate that Vanda Pharmaceuticals will post ($0.44) earnings per share for the current fiscal year.

WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Earns “Buy” Rating from Oppenheimer Holdings, Inc.” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/14/vanda-pharmaceuticals-inc-vnda-earns-buy-rating-from-oppenheimer-holdings-inc.html.

Hedge funds have recently made changes to their positions in the company. Birchview Capital LP raised its holdings in shares of Vanda Pharmaceuticals by 25.9% in the second quarter. Birchview Capital LP now owns 68,000 shares of the biopharmaceutical company’s stock valued at $1,108,000 after purchasing an additional 14,000 shares during the last quarter. Weiss Multi Strategy Advisers LLC raised its holdings in shares of Vanda Pharmaceuticals by 20.0% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 60,000 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 10,000 shares during the last quarter. American International Group Inc. raised its holdings in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after purchasing an additional 1,491 shares during the last quarter. Prudential Financial Inc. raised its holdings in shares of Vanda Pharmaceuticals by 0.8% in the first quarter. Prudential Financial Inc. now owns 614,318 shares of the biopharmaceutical company’s stock valued at $8,600,000 after purchasing an additional 4,700 shares during the last quarter. Finally, FMR LLC raised its holdings in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock valued at $22,416,000 after purchasing an additional 604,900 shares during the last quarter. Institutional investors own 86.49% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.